Literature DB >> 3235305

Experience with brulamycin therapy in dialysed patients.

L Löcsey1, E Faragó, G Kakuk.   

Abstract

Forty-two patients with chronic renal insufficiency were subjected to Brulamycin therapy to combat complications such as sepsis, infection of the lower respiratory tract (bronchopneumonia) or of the urinary tract, Cimino fistula inflammation or peritonitis when the pathogenic agent was sensitive to nothing but aminoglycosides. The proper Brulamycin dose was selected under close clinical and laboratory control so as to fit the dialysed patient and his state of impaired renal function. The various forms of dialysis have been studied to determine their Brulamycin blood level diminishing effects. Familiarity with these effects is as important as with the patient's age, sex, body weight and actual state of renal function. The results confirm the experience gained by other authors that Brulamycin treatment--in curative non-toxic doses as indicated by the blood level index--is useful against severe infectious complications in anuric patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3235305     DOI: 10.1007/bf02550617

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  15 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Analysis of gentamicin uptake by rat renal cortical slices.

Authors:  W M Kluwe; J B Hook
Journal:  Toxicol Appl Pharmacol       Date:  1978-08       Impact factor: 4.219

3.  Aztreonam: a monocyclic beta-lactam antibiotic.

Authors: 
Journal:  Am J Med       Date:  1985-02-08       Impact factor: 4.965

4.  [Microbiological effectiveness, pharmacokinetics and clinical use of tobramycin].

Authors:  H Graber; M Arr; T Deutsch; E Ludwig; T Magyar
Journal:  Orv Hetil       Date:  1980-01-27       Impact factor: 0.540

5.  Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.

Authors:  C Cojocel; N Dociu; E Ceacmacudis; K Baumann
Journal:  Nephron       Date:  1984       Impact factor: 2.847

6.  Increased burn patient survival with individualized dosages of gentamicin.

Authors:  D E Zaske; J L Bootman; L B Solem; R G Strate
Journal:  Surgery       Date:  1982-02       Impact factor: 3.982

7.  Risk factors for nephrotoxicity in patients treated with aminoglycosides.

Authors:  R D Moore; C R Smith; J J Lipsky; E D Mellits; P S Lietman
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

8.  Patterns of urinary beta 2-microglobulin excretion by patients treated with aminoglycosides.

Authors:  J J Schentag; M E Plaut
Journal:  Kidney Int       Date:  1980-05       Impact factor: 10.612

9.  Gentamicin dosing errors with four commonly used nomograms.

Authors:  T S Lesar; J C Rotschafer; L M Strand; L D Solem; D E Zaske
Journal:  JAMA       Date:  1982-09-10       Impact factor: 56.272

10.  Amikacin: in vitro bacteriological studies, levels in human serum, lung and heart tissue, and clinical results.

Authors:  E Faragó; J Kiss; A Gömöry; J Aranyosi; I Juhász; L Mihóczy
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.